Citigroup Issues Pessimistic Forecast for Candel Therapeutics (NASDAQ:CADL) Stock Price

Candel Therapeutics (NASDAQ:CADL – Get Free Report) had its price objective decreased by analysts at Citigroup from $26.00 to $20.00 in a report released on Monday, Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup‘s target price would suggest a potential upside of 270.37% from the company’s current price.

Other equities research analysts also recently issued reports about the stock. Zacks Research downgraded shares of Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. UBS Group reiterated a “buy” rating on shares of Candel Therapeutics in a research report on Monday, August 17th. HC Wainwright lowered their price target on shares of Candel Therapeutics from $23.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, November 13th. Stifel Nicolaus cut their price objective on shares of Candel Therapeutics from $22.00 to $19.00 and set a “buy” rating for the company in a research report on Friday, November 13th. Finally, Jefferies Financial Group assumed coverage on shares of Candel Therapeutics in a research note on Thursday, October 22nd. They set a “buy” rating and a $25.00 price objective for the company. Nine equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $18.29.

View Our Latest Analysis on Candel Therapeutics

Candel Therapeutics Trading Down 7.1%

Shares of CADL stock opened at $5.40 on Monday. Candel Therapeutics has a 52-week low of $4.35 and a 52-week high of $14.00. The company has a 50-day simple moving average of $9.47 and a two-hundred day simple moving average of $8.39. The company has a market capitalization of $423.63 million, a price-to-earnings ratio of -3.65 and a beta of -0.27. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.57 and a current ratio of 7.57.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. Research analysts anticipate that Candel Therapeutics will post -1.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Candel Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in Candel Therapeutics in the second quarter valued at approximately $51,181,000. Portolan Capital Management LLC lifted its position in Candel Therapeutics by 1.4% during the third quarter. Portolan Capital Management LLC now owns 3,538,561 shares of the company’s stock valued at $36,943,000 after purchasing an additional 48,163 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Candel Therapeutics by 4.1% during the third quarter. Goldman Sachs Group Inc. now owns 317,601 shares of the company’s stock valued at $3,316,000 after purchasing an additional 12,385 shares during the last quarter. Bank of America Corp DE bought a new stake in Candel Therapeutics during the second quarter valued at approximately $2,873,000. Finally, Wellington Management Group LLP purchased a new position in Candel Therapeutics in the 2nd quarter worth approximately $2,119,000. 13.93% of the stock is currently owned by institutional investors.

Latest Candel Therapeutics News

Investors following CADL have been watching these news items:

  • Neutral Sentiment: HC Wainwright maintained its Buy rating and $18 price target, while raising its FY2026 loss estimate. The target is a supportive signal, but the firm’s longer-range forecasts were cut substantially. MarketBeat analyst estimates
  • Negative Sentiment: HC Wainwright lowered projected earnings for FY2027 through FY2030, including moving its FY2028 estimate from a profit to a loss. Brookline’s estimates also point to ongoing quarterly losses through 2027, reinforcing concerns about the path to profitability. MarketBeat analyst estimates
  • Negative Sentiment: Law firms announced investigations and investor notices following Candel’s delay of its aglatimagene biologics license application (BLA) for prostate cancer to mid-2027. The notices allege potential securities-law issues; they are not findings of wrongdoing. The filing delay had already triggered a sharp selloff, and the legal scrutiny could add uncertainty. SBS Law investigation notice Levi and Korsinsky investigation notice

About Candel Therapeutics

(Get Free Report)

Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.

Recommended Stories

Analyst Recommendations for Candel Therapeutics (NASDAQ:CADL)

Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.